Stocks of Cogent Biosciences Inc (NASDAQ:COGT) traded higher last session on Wall Street, up 4.60% to $9.78.
COGT stock price is now 59.66% away from the 50-day moving average and 22.96% away from the 200-day moving average. The market capitalization of the company currently stands at $1.11B.
With the price target of $17, Scotiabank recently initiated with Sector Outperform rating for Cogent Biosciences Inc (NASDAQ: COGT). , while ‘Robert W. Baird’ rates the stock as ‘Neutral’
In other news, Pinnow Cole, Chief Commercial Officer bought 43,750 shares of the company’s stock on Jan 14 ’25. The stock was bought for $332,412 at an average price of $7.60. Upon completion of the transaction, the Chief Commercial Officer now directly owns 45,848 shares in the company, valued at $0.45 million. A total of 17.41% of the company’s stock is owned by insiders.
During the past 12 months, Cogent Biosciences Inc has had a low of $3.72 and a high of $12.61. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 5.13, and a quick ratio of 5.13. The fifty day moving average price for COGT is $6.1254 and a two-hundred day moving average price translates $7.95405 for the stock.
The latest earnings results from Cogent Biosciences Inc (NASDAQ: COGT) was released for 2025-03-31.
